STORM’s METTL3 Inhibitor Effective Against AML
Plans Global Clinical RNA Epigenetic Drug Program in early 2022
Emerging Company Profile: STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML.
You may also be interested in...
By jointly finding a first-in-class atypical Protein Kinase C inhibitor preclinical candidate, Israel’s Teva and Britain’s Cancer Research Technology have successfully capped a four-year collaboration and are now branching out into the area of DNA damage response.
Emerging Company Profile: While vaccines target specific viruses, Dutch start-up Leyden Labs is hunting down commonalities in viral families and working on the delivery of intranasal molecules that can protect humans from both known and future viruses.
Pandemic Perspectives: Acacia CEO Says Pre-Existing Commercial Relationships, End-User Backing Key To Product Launches
Despite sector lockdowns there, Acacia has just launched two hospital-based products in the US. Its CEO Mike Bolinder tells Scrip how it defied the pandemic to get its drugs to their users.